Article Details
Retrieved on: 2025-01-13 20:37:13
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses a legal dispute involving intellectual property law, specifically focusing on the European Union's SPC manufacturing waiver, between Amgen Inc. and Samsung Bioepis over biosimilar manufacturing. The Brussels Court sided with Samsung Bioepis, interpreting the SPC Regulation flexibly. The case highlights ongoing challenges in harmonizing patent law across EU jurisdictions.
Article found on: www.allenovery.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here